研究放射性药物治疗与PARP抑制剂联合治疗的数学模型
本研究建立数学模型定量表征同源重组缺陷,基于DNA吸收剂量和放射生物学反应预测放射性药物治疗与PARP抑制剂联合疗效。体外实验校准验证显示平均偏差5.3±3.2%(无PARPi)、6.1±4.4%(奥拉帕利)、12±18%(芦卡帕利),他拉唑帕利体外放射增敏效应最高(IC50: 4.8 nM)。
要点
- 模型以DNA双链断裂为癌细胞命运关键决定因素,PARPi效应通过S期PARP捕获加速单链断裂向双链断裂转化来建模。
- 模型验证平均偏差:无PARPi 5.3±3.2%,奥拉帕利6.1±4.4%,芦卡帕利12±18%。
- 他拉唑帕利体外放射增敏效应最高(IC50: 4.8 nM),其次为芦卡帕利(IC50: 1.4 µM)。
核心结论
- 结果表明该计算模型有潜力作为开发数字孪生的一步,用于系统探索和优化临床方案。
研究设计与样本
- 本研究引入数学模型定量表征同源重组缺陷,基于DNA吸收剂量和放射生物学反应预测疗效。
- 使用NCI-H69细胞经[177Lu]Lu-DOTA-TOC和PARPi处理的体外实验数据校准模型参数并验证模型。
- 设计计算机模拟试验广泛研究多种联合方案,包括LuPARP试验。
主要发现
- 模型验证使用体外数据,偏差在实验误差范围内,无PARPi时平均偏差5.3±3.2%,奥拉帕利时6.1±4.4%,芦卡帕利时12±18%。
- 芦卡帕利放射增敏使镥治疗期间肿瘤细胞数量减少99.2%(非HRD)和99.99%(HRD)。
- 体外和体内放射增敏效应最高为他拉唑帕利(IC50: 4.8 nM),其次为芦卡帕利(IC50: 1.4 µM)。
- 模型预测基于患者体重的奥拉帕利(250 mg)联合治疗14天后相对肿瘤缩小:60 kg为99.6%,90 kg为98.0%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the combined treatment with radiopharmaceutical therapy (RPT) and poly (ADP-ribose) polymerase inhibitors (PARPi) shows promise, a critical challenge remains in the limited quantitative understanding needed to optimize treatment protocols. This study introduces a mathematical model that quantitatively represents homologous recombination deficiency (HRD) and facilitates patient-specific customization of therapeutic schedules. METHODS: The model predicts therapeutic outcomes based on the absorbed dose by DNA and the resulting radiobiological responses, with DNA double-strand breaks (DSBs) being the critical determinant of cancer cell fate. The effect of PARPi is modeled by the accelerated conversion of single-strand breaks (SSBs) to DSBs due to PARP-trapping in the S phase, while HRD is represented by defects in DSB repair in replicated DNA. In vitro experiments are used to calibrate the model parameters and validate the model. In silico tests are designed to extensively investigate various combination protocols including the LuPARP trial. RESULTS: Model calibration was performed using data from the treatment of NCI-H69 cells with [177Lu]Lu-DOTA-TOC and PARPi. Previously published in vivo studies were integrated into the presented model. Model validation using in vitro data showed deviations within the experimental error margins, with average deviations of 5.3 ± 3.2% without PARPi, 6.1 ± 4.4% with Olaparib, and 12 ± 18% with Rucaparib. Rucaparib radiosensitization reduces number of tumor cells during lutetium therapy by 99.2% and 99.99% (HRD). The highest radiosensitizing effect in vivo and in vitro was observed with Talazoparib (IC50: 4.8 nM), followed by Rucaparib (IC50: 1.4 µM). The model predicts relative tumor shrinkage after 14 days of combination treatment with Olaparib (250 mg) based on patient body weight (e.g. 60 kg: 99.6%; 90 kg: 98.0%). CONCLUSION: Results demonstrate the potential of this computational model as a step toward the development of the digital twin for systematic exploration and optimization of clinical protocols.
引用
- Ryhiner M, Song Y, Hong J, et al. A mathematical model for the investigation of combined treatment of radiopharmaceutical therapy and PARP inhibitors. Eur J Nucl Med Mol Imaging. 2025. PMID: 40000461. doi:10.1007/s00259-025-07144-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。